

Impact of Definitive Drug-Drug Interaction Testing on Medication Management and Patient Care

Drugs – Real World Outcomes

Renée JG Arnold, Alison Tradonsky, Jun Tang, Joshua Schrecker, Cheryl Hild

*Corresponding author:

Renée JG Arnold, PharmD

Arnold Consultancy & Technology, LLC

15 West 72nd Street – 23rd Floor, New York, NY 10023

917-945-3267

rarnold@arnoldllc.com; renee.arnold@mssm.edu

Appendix I. Excerpt of laboratory report

Laboratory Report

Clinic Information

Client: Healthcare Client
123 Any St
Anytown, US 12345
Requesting Provider:
Dr. John Doe

Patient Information

Patient Name: Jane Doe

Patient ID:
Date of Birth: 12/01/1984
Male/Female: Female

Sample Information

Lab Sample ID: 12345678
Specimen Type: Urine
Collected: 3/22/2018
Received: 3/23/2018
Reported: 3/25/2018

Medication(s) Prescribed

Oxycodone

Test(s) Requested

00197IU - QMP Plus D/L
00021 - Drug-Drug Interaction (DDI)

Medication Compliance			
Drug and/or Metabolites	Result Interpretation	Normalized Result	Comment
Oxycodone	PRESENT	7,000 ng/mL	Test result is consistent and expected with prescribed drug.

Drug-Drug Interaction (DDI)			
Potential Interaction Detected		Interaction Severity	Interaction Description
Oxycodone	Ritonavir (Norvir)	SEVERE	The concurrent administration of a CYP3A4 inhibitor may result in elevated levels of and toxicity from alfentanil, fentanyl(1,2) hydrocodone(3) and oxycodone(4), including somnolence and potentially fatal respiratory depression.
Darunavir (Prezista)	Oxycodone	MODERATE	The concurrent administration of a CYP3A4 inhibitor may result in elevated levels of and toxicity from alfentanil, fentanyl(1,2) and oxycodone(3), including somnolence and potentially fatal respiratory depression.

Citations in interaction descriptions can be provided as needed. Please contact Clinical Scientists at 1-877-552-3232 for more information.